| Autor: |
Allan SG, Cornbleet MA, Lockhart SP, Warrington PS, Leonard RC, Smyth JF |
| Jazyk: |
angličtina |
| Zdroj: |
European journal of cancer & clinical oncology [Eur J Cancer Clin Oncol] 1984 Dec; Vol. 20 (12), pp. 1481-4. |
| DOI: |
10.1016/0277-5379(84)90140-8 |
| Abstrakt: |
A randomised, double-blind prospective trial was conducted to determine the relative anti-emetic efficacy of three dose levels of metoclopramide in cancer patients receiving combination chemotherapy including cis-platinum. With consecutive courses of chemotherapy, 60 patients received doses of either 3,5 or 10 mg/kg metoclopramide (50, 54 or 55 courses respectively) in a randomly assigned sequence. Major control of emesis (less than or equal to 2 vomits) was achieved in 38% of 159 patient treatments. There were no significant differences in either anti-emetic efficacy or the incidence of side-effects between the three doses used. It is concluded that while metoclopramide is an effective anti-emetic for patients receiving cisplatinum therapy, no advantage accrues to the use of doses in excess of 3 mg/kg (total dose). |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
